T细胞治疗癌症的漫长之路：从使用非特异性细胞产物的过继性免疫疗法到供体淋巴细胞输注以及工程化肿瘤特异性T细胞的转移。
A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.
作者信息
Spyridonidis Alexandros, Liga Maria
机构信息
Hematology Division, BMT Unit, University Hospital of Patras 26500 Rio, Greece.
出版信息
Am J Blood Res. 2012;2(2):98-104. Epub 2012 May 18.
Abstract
The notion that immunocompetent cells, contained within adult bone marrow or peripheral blood, are capable of mediating an antitumor effect was first validated experimentally in 1957. T-cell immunotherapy for malignant disease is now routinely used in the context of allogeneic bone marrow transplantation. After 50 years of investigations into the use of T-cells for cancer therapy, adoptive cellular immunotherapy for cancer has progressed from the delivery of unspecific cellular products to the transfer of engineered tumor-specific T-cells. Adoptive cellular immunotherapy for cancer has now reached a stage of increasing feasibility and efficacy.
摘要
1957年，成人骨髓或外周血中所含的免疫活性细胞能够介导抗肿瘤作用这一观念首次得到实验验证。目前，在异基因骨髓移植中，针对恶性疾病的T细胞免疫疗法已被常规使用。在对T细胞用于癌症治疗进行了50年的研究之后，癌症的过继性细胞免疫疗法已从递送非特异性细胞产物发展到移植工程化肿瘤特异性T细胞。癌症的过继性细胞免疫疗法目前已进入可行性和疗效不断提高的阶段。
相似文献
1
2
Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.重组人白细胞介素-2联合骨髓移植用于控制恶性血液系统疾病微小残留病的模型：I. 联合异基因骨髓移植和白细胞介素-2激活的细胞介导免疫疗法治疗小鼠白血病
Cancer Invest. 1992;10(1):19-26. doi: 10.3109/07357909209032785.
3
New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.异基因干细胞移植的新策略：使用辐照后的异基因T细胞进行免疫治疗。
Bone Marrow Transplant. 2000 May;25 Suppl 2:S20-4. doi: 10.1038/sj.bmt.1702347.
4
Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.将骨髓移植供体进行肿瘤抗原特异性免疫接种作为针对已形成肿瘤的过继性疗法。
J Natl Cancer Inst. 1995 Sep 6;87(17):1289-96. doi: 10.1093/jnci/87.17.1289.
5
Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.供体淋巴细胞输注：将同种异体反应性和肿瘤反应性淋巴细胞用于恶性和非恶性疾病的免疫治疗，并与异基因干细胞移植联合使用。
J Hematother Stem Cell Res. 2002 Apr;11(2):265-76. doi: 10.1089/152581602753658457.
6
Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.移植物抗宿主病的抗白血病和抗肿瘤作用：一种新的免疫病毒学方法。
Acta Microbiol Immunol Hung. 2010 Dec;57(4):253-347. doi: 10.1556/AMicr.57.2010.4.2.
7
Adoptive immunotherapy with donor lymphocyte transfusions.
Curr Opin Oncol. 1997 Mar;9(2):139-45. doi: 10.1097/00001622-199703000-00006.
8
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.通过转移供体的T细胞克隆来重建异基因骨髓受体针对巨细胞病毒的细胞免疫。
N Engl J Med. 1995 Oct 19;333(16):1038-44. doi: 10.1056/NEJM199510193331603.
9
Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.
J Immunother. 1998 Nov;21(6):447-53. doi: 10.1097/00002371-199811000-00007.
10
Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy.输血医学：细胞免疫疗法的新临床应用
Hematology Am Soc Hematol Educ Program. 2000:356-375. doi: 10.1182/asheducation-2000.1.356.
本文引用的文献
1
Defining the critical hurdles in cancer immunotherapy.定义癌症免疫疗法的关键障碍。
J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.
2
Inducible apoptosis as a safety switch for adoptive cell therapy.诱导细胞凋亡作为过继细胞治疗的安全开关。
N Engl J Med. 2011 Nov 3;365(18):1673-83. doi: 10.1056/NEJMoa1106152.
3
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.异基因干细胞移植后出现混合嵌合体证据的儿童急性髓细胞白血病的抢先免疫治疗。
Blood. 2011 Nov 17;118(20):5681-8. doi: 10.1182/blood-2011-04-348805. Epub 2011 Sep 26.
4
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.嵌合抗原受体修饰的 T 细胞治疗慢性淋巴细胞白血病。
N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10.
5
CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia.CT60 单核苷酸多态性作为异基因细胞移植治疗急性白血病后供者淋巴细胞输注结果的替代标志物。
Bone Marrow Transplant. 2012 Mar;47(3):411-5. doi: 10.1038/bmt.2011.101. Epub 2011 May 9.
6
Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.免疫反应的表观遗传调控：血液系统恶性肿瘤的一种新型治疗策略。
Cytotherapy. 2011 May;13(5):516-7. doi: 10.3109/14653249.2011.561652. Epub 2011 Mar 7.
7
Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia.极低剂量阿仑单抗在急性白血病移植中的药代动力学和临床活性。
Bone Marrow Transplant. 2011 Oct;46(10):1363-8. doi: 10.1038/bmt.2010.308. Epub 2010 Dec 20.
8
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).使用透气快速扩增培养器（G-Rex）加速用于临床前和临床应用的抗原特异性 T 细胞的生产。
J Immunother. 2010 Apr;33(3):305-15. doi: 10.1097/CJI.0b013e3181c0c3cb.
9
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.移植受者中预防或治疗 EBV 相关淋巴增殖性疾病的 EBV 特异性 T 细胞输注的长期结果。
Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30.
10
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.在异基因造血干细胞移植后复发的老年急性髓系白血病或慢性粒单核细胞白血病患者中，5-氮杂胞苷 3 天低剂量治疗继以供者淋巴细胞输注的疗效。
Bone Marrow Transplant. 2010 Apr;45(4):627-32. doi: 10.1038/bmt.2009.222. Epub 2009 Aug 31.
Zotero 插件